A retrospective study of efficacy of ICIs (nivolumab or pembrolizumab) and chemotherapy (carboplatin with paclitaxel) for stage IIIA-B non-small cell lung cancer patients
Latest Information Update: 22 Mar 2022
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 22 Mar 2022 New trial record
- 01 Mar 2022 Results published in the Annals of Thoracic Surgery